[Source: The Medical News] – Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer’s disease (AD). AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040. For the first time in AD research, scientists are about to test the efficacy of a gene transfer therapy called CERE-110.
Previously, CERE-110 was studied in a small study to assess safety. These studies showed that CERE-110 can induce long-term production of Nerve Growth Factor (NGF) by brain cells. Researchers are now seeking 50 study participants with mild to moderate AD for a Phase 2 clinical study at 12 U.S. research sites, including Banner Sun Health research Institute.
For more information: Researchers commence Phase 2 research study to test CERE-110 for AD